Journal Article

DKFZ-2024-01235

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Multicentric Assessment of Safety and Efficacy of Combinatorial Adjuvant Brain Metastasis Treatment by Intraoperative Radiation Therapy and Immunotherapy.

Layer, J. P. ; Shiban, E. ; Brehmer, S. ; Diehl, C. D. ; de Castro, D. G. ; Hamed, M. ; Dejonckheere, C. S. ; Cifarelli, D. T. ; Friker, L. L. ; Herrlinger, U. ; Hölzel, M. ; Vatter, H. ; Schneider, M. ; Combs, S. E. ; Schmeel, L. C. ; Cifarelli, C. P. ; Giordano, F. A.DKFZ* ; Sarria, G. R. ; Kahl, K.-H.

2024
Elsevier Science Amsterdam [u.a.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1016/j.ijrobp.2024.01.009

Abstract: After surgical resection of brain metastases (BMs), intraoperative radiation therapy (IORT) provides a promising alternative to adjuvant external beam radiation therapy by enabling superior organ-at-risk preservation, reduction of in-hospital times, and timely admission to subsequent systemic treatments, which increasingly comprise novel targeted immunotherapeutic approaches. We sought to assess the safety and efficacy of IORT in combination with immune checkpoint inhibitors (ICIs) and other targeted therapies (TTs).In a multicentric approach incorporating individual patient data from 6 international IORT centers, all patients with BMs undergoing IORT were retrospectively assessed for combinatorial treatment with ICIs/TTs and evaluated for toxicity and cumulative rates, including wound dehiscence, radiation necrosis, leptomeningeal spread, local control, distant brain progression (DBP), and estimated overall survival.In total, 103 lesions with a median diameter of 34 mm receiving IORT combined with immunomodulatory systemic treatment or other TTs were included. The median follow-up was 13.2 (range, 1.2-102.4) months, and the median IORT dose was 25 (range, 18-30) Gy prescribed to the applicator surface. There was 1 grade 3 adverse event related to IORT recorded (2.2%). A 4.9% cumulative radiation necrosis rate was observed. The 1-year local control rate was 98.0%, and the 1-year DBP-free survival rate was 60.0%. Median time to DBP was 5.5 (range, 1.0-18.5) months in the subgroup of patients experiencing DBP, and the cumulative leptomeningeal spread rate was 4.9%. The median estimated overall survival was 26 (range, 1.2 to not reached) months with a 1-year survival rate of 74.0%. Early initiation of immunotherapy/TTs was associated with a nonsignificant trend toward improved DBP rate and overall survival.The combination of ICIs/TTs with IORT for resected BMs does not seem to increase toxicity and yields encouraging local control outcomes in the difficult-to-treat subgroup of larger BMs. Time gaps between surgery and systemic treatment could be shortened or avoided. The definitive role of IORT in local control after BM resection will be defined in a prospective trial.

Keyword(s): Humans (MeSH) ; Prospective Studies (MeSH) ; Retrospective Studies (MeSH) ; Combined Modality Therapy (MeSH) ; Brain Neoplasms: radiotherapy (MeSH) ; Brain Neoplasms: secondary (MeSH) ; Immunotherapy: adverse effects (MeSH) ; Necrosis (MeSH) ; Neoplasm Recurrence, Local (MeSH)

---

Contributing Institute(s):

1. DKFZ-Hector Krebsinstitut (wiss. Leitung einer AG) (M028)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2024

---

Database coverage:
; ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---